Cipla Limited

CIPLA

INE059A01026

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 06:22:26 2024-04-25 am EDT			5-day change	1st Jan Change
1,406 ^INR	+0.57%		+4.37%	+12.83%

Apr. 24	Indian Equities End Higher Midweek as Iran-Israel Conflict Subsides	MT
Apr. 19	Cipla Limited Receives Order from the GST Authority	CI

Cipla Limited Receives the Establishment Inspection Report Indicating Closure of the Inspection

September 22, 2022 at 07:41 am EDT

Cipla Limited announced that following the product specific Pre-Approval Inspection (PAI) by the United States Food and Drug Administration (USFDA) at the Indore plant from June 27, 2022 to July 1, 2022, the Company has now received the Establishment Inspection Report (EIR) indicating closure of the inspection.

Latest news about Cipla Limited

Indian Equities End Higher Midweek as Iran-Israel Conflict Subsides	Apr. 24	MT
Cipla Limited Receives Order from the GST Authority	Apr. 19	CI
India's Biocon developing its own version of Wegovy, clinical trial likely next year	Apr. 18	RE
Cipla's Consumer Healthcare Arm to Acquire Ivia's Cosmetics, Personal-Care Marketing Business	Apr. 16	MT
Indian Equities End Higher on Wednesday, Lifted Mainly by Metal Stocks	Apr. 10	MT
Cipla Receives US FDA Observations Following Patalganga Facility Inspection	Apr. 05	MT
Cipla Gets Regulatory Nod to Merge US-Based Subsidiaries	Mar. 26	MT
Cipla to Distribute Sanofi's CNS Product Line in India	Mar. 26	MT
Cipla Limited Appoints Rajeev Kumar Sinha as Senior Management Personnel and Global Chief Manufacturing Officer, Effective April 1, 2024	Mar. 26	CI
Sanofi India Limited, Sanofi Healthcare India Private Limited and Cipla Limited Announce an Exclusive Partnership	Mar. 26	CI
Losses Led by IT Drag Indian Equities on Tuesday	Mar. 19	MT
Cipla Limited Appoints Venkata Sai Mungara as Senior Management Personnel and Global Head - Supply Chain, Effective from 1 April 2024	Mar. 15	CI
Indian Equities Close with Marginal Gains on Tuesday as IT Stocks See Drop	Mar. 12	MT
Cipla Arm Completes Sale of Entire Stake in Wellthy	Mar. 07	MT
India pharma companies develop versions of Wegovy to get in on weight-loss windfall	Feb. 22	RE
Indian Equities Close Higher Midweek, Led by Banking, IT Stocks	Feb. 14	MT
Indian drugmaker Lupin beats quarterly profit estimates on strong demand	Feb. 07	RE
Indian drugmaker J B Chemicals posts Q3 profit rise on strong demand	Feb. 06	RE
India's Alembic Pharma beats Q3 profit view on strong domestic, US sales	Feb. 05	RE
Cipla Eyes Acquisitions and Inorganic Partnerships in the US, European markets	Feb. 04	CI
India's Jubilant Pharmova posts quarterly profit	Feb. 02	RE
India's Torrent Pharma posts higher Q3 profit on strong domestic demand	Feb. 02	RE
Loss in Bank Stocks Drags Indian Equities to End Lower on Thursday	Feb. 01	MT
Indian pharma firm Dr Reddy's beats Q3 profit view on strong US, European businesses	Jan. 30	RE
Nomura Downgrades Cipla to Neutral From Buy, Price Target to INR1,427 From INR1,353	Jan. 30	MT

Chart Cipla Limited

Duration

Period

More charts

Company Profile

Cipla specializes in development, manufacturing and marketing of pharmaceutical products. The group provides prescription products and OTC medicines for the treatment of cardiovascular, ophthalmic and dermatological diseases, respiratory troubles, cancers, allergies, infections etc. Besides, Cipla develops and sells veterinary products. Net sales by source of income break down between sale of products (96.9%) and services (3.1%). Net sales are distributed geographically as follows: India (39.4%), the United States (18.5%), South Africa (17%) and other (25.1%).

Sector

Pharmaceuticals

Calendar

2024-05-09 - Q4 2024 Earnings Release

Related indices

NIFTY 50 , NIFTY 100

More about the company

Income Statement Evolution

More financial data

Ratings for Cipla Limited

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,398 INR

Average target price

1,453 INR

Spread / Average Target

+3.90%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
CIPLA LIMITED	+12.83%	13.55B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.70%	42.78B
OTSUKA HOLDINGS CO., LTD.	+18.59%	22.25B
SANDOZ GROUP AG	+14.78%	14.39B
ZYDUS LIFESCIENCES LIMITED	+38.02%	11.27B
ONO PHARMACEUTICAL CO., LTD.	-9.80%	6.95B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+6.29%	5.01B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-8.24%	4.51B

Generic Pharmaceuticals

Cipla Limited

Equities

CIPLA

INE059A01026

Pharmaceuticals

Cipla Limited Receives the Establishment Inspection Report Indicating Closure of the Inspection

EPS Revisions